ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
2005
ZD6474: A New Cancer Treatment
publication
Evidence: high
Author Information
Author(s): Ryan A J, Wedge S R
Primary Institution: Department of Cancer and Infection Research, AstraZeneca
Hypothesis
ZD6474 inhibits VEGFR and EGFR tyrosine kinase activity.
Conclusion
ZD6474 shows significant antitumor activity by inhibiting key pathways in tumor growth.
Supporting Evidence
- ZD6474 inhibits VEGF-induced signaling in endothelial cells.
- ZD6474 shows broad-spectrum antitumor activity in diverse human tumor xenografts.
- ZD6474 inhibits both VEGFR-2 and EGFR tyrosine kinase activities.
Takeaway
ZD6474 is a medicine that helps stop cancer from growing by blocking signals that tumors need to grow.
Methodology
Preclinical studies evaluated the effects of ZD6474 on tumor growth and angiogenesis in various cancer models.
Statistical Information
P-Value
P=0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website